Literature DB >> 20977485

Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function.

Ana M Galan1, Miguel Lozano, Patricia Molina, Fulgencio Navalon, Sussane Marschner, Raymond Goodrich, Ginés Escolar.   

Abstract

BACKGROUND: There are limited studies on the effect of pathogen reduction technology (PRT) on platelet (PLT) products stored in PLT additive solutions (PASs). Our study has evaluated the effect of Mirasol PRT (CaridianBCT) followed by storage in PASs (PAS-III or PAS-IIIM) on analytical and functional characteristics of PLT concentrates (PCs). STUDY DESIGN AND METHODS: PCs obtained by apheresis were divided into: 1) untreated and stored in plasma (CON-PPP); 2) untreated and stored in PAS (CON-PASIII and CON-PASIIIM); and 3) subjected to PRT and stored in PAS (PRT-PASIII and PRT-PASIIIM). Cell quality variables (pH, swirl, lactate, and glucose), flow cytometry analysis, and adhesive and aggregating functions using a perfusion system were assessed on Days 0, 3, 5, and 7.
RESULTS: All the groups showed a progressive reduction in cell quality variables during storage. Swirl was progressively reduced and better maintained in CON-PPP. Flow cytometry analysis revealed a moderate reduction in glycoprotein Ib for all study groups on Day 7, being less evident in CON-PPP. A progressive increase in P-selectin levels was observed during storage. Perfusion studies demonstrated that PRT-treated PCs stored in PAS presented similar reactivity with subendothelium than that observed for untreated PCs stored in plasma or in PAS for Day 5. Moderate reductions in cohesive properties in PRT-PASIII PCs, but not in PRT-PASIIIM PCs, were observed after 7 days.
CONCLUSIONS: PLT properties were preserved in PRT-treated concentrates stored in PAS for 5 days. PASIIIM provides a better preservation of adhesive and cohesive functions of PRT-PCs than PASIII for 7 days of storage. The relevance of in vitro data deserves further clinical investigations.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977485     DOI: 10.1111/j.1537-2995.2010.02914.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

Review 2.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

3.  Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.

Authors:  Heather F Pidcoke; Steve J McFaul; Anand K Ramasubramanian; Bijaya K Parida; Alex G Mora; Chriselda G Fedyk; Krystal K Valdez-Delgado; Robbie K Montgomery; Kristin M Reddoch; Armando C Rodriguez; James K Aden; John A Jones; Ron S Bryant; Michael R Scherer; Heather L Reddy; Raymond P Goodrich; Andrew P Cap
Journal:  Transfusion       Date:  2013-01       Impact factor: 3.157

4.  The Effects of Ultraviolet Light and Riboflavin on Inactivation of Viruses and the Quality of Platelet Concentrates at Laboratory Scale.

Authors:  Hamideh Mirshafiee; Zohreh Sharifi; Syed Masoud Hosseini; Fatemeh Yari; Hamed Nikbakht; Hamid Latifi
Journal:  Avicenna J Med Biotechnol       Date:  2015 Apr-Jun

5.  Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.

Authors:  Gines Escolar; Victor Fernandez-Gallego; Eduardo Arellano-Rodrigo; Jaume Roquer; Joan Carles Reverter; Victoria Veronica Sanz; Patricia Molina; Irene Lopez-Vilchez; Maribel Diaz-Ricart; Ana Maria Galan
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

6.  In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.

Authors:  Nicolas Malvaux; Fanette Defraigne; Styliani Bartziali; Camille Bellora; Kathleen Mommaerts; Fay Betsou; Anne Schuhmacher
Journal:  Pathogens       Date:  2022-03-11

Review 7.  Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.

Authors:  Gines Escolar; Maribel Diaz-Ricart; Jeffrey McCullough
Journal:  Transfusion       Date:  2021-12-06       Impact factor: 3.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.